Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
Cells. 2022 Feb 12;11(4):645. doi: 10.3390/cells11040645.
Ketamine is a rapid-acting antidepressant with proven efficacy as an add-on agent in unipolar and bipolar treatment-resistant depression. Although many studies have been published, there is still not enough data on the effect of ketamine in combination with other medications. Particularly interesting is the combination of ketamine and lamotrigine, and its potential role in bipolar depression. The aim of this review was to identify animal and human studies in which ketamine and lamotrigine were used together in order to find out if there is scientific ground for combining ketamine and lamotrigine in the treatment of mood disorders. Directions for future studies are presented.
PubMed and Web of Science were searched. Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA 2020 methodology was applied.
Seventeen studies were included for review. Animal studies using models of depression suggested a synergistic effect of ketamine and lamotrigine in combination. Studies on healthy humans showed a reduction in ketamine-induced dissociative symptoms with lamotrigine pretreatment. In a study on patients with depression, ketamine and lamotrigine did not have a stronger antidepressant effect than ketamine alone, but in this study only one ketamine infusion was administered. One case series described the antidepressant and anti-suicidal effect of the combination in two bipolar patients. Available clinical studies on patients with mood disorders did not support the hypothesis that lamotrigine reduces ketamine-induced dissociative symptoms.
The results of the analyzed studies were not sufficient to answer any of the stated questions; however, they allowed us to delineate future research directions. The identified animal studies suggested a possible synergistic antidepressant effect of ketamine and lamotrigine. The available clinical studies were not conclusive. No controlled studies on large groups of bipolar patients with multiple ketamine infusions combined with lamotrigine treatment have been published so far. There is some evidence for the reduction of ketamine's side effects by lamotrigine, and there are reports suggesting that lamotrigine can reduce ketamine craving. More studies with follow-up are needed in order to investigate the ketamine-lamotrigine combination in bipolar patients.
氯胺酮是一种快速起效的抗抑郁药,已被证明可作为单相和双相治疗抵抗性抑郁症的附加治疗药物。尽管已经发表了许多研究,但关于氯胺酮与其他药物联合使用的效果仍缺乏足够的数据。特别有趣的是氯胺酮与拉莫三嗪联合使用,及其在双相抑郁症中的潜在作用。本综述的目的是确定动物和人体研究中使用氯胺酮和拉莫三嗪联合治疗的研究,以确定在治疗心境障碍时联合使用氯胺酮和拉莫三嗪是否有科学依据。并提出了未来研究的方向。
检索了 PubMed 和 Web of Science。应用了系统评价和荟萃分析的首选报告项目 PRISMA 2020 方法。
纳入了 17 项研究进行综述。使用抑郁症模型的动物研究表明,氯胺酮和拉莫三嗪联合使用具有协同作用。对健康人类的研究表明,拉莫三嗪预处理可降低氯胺酮诱导的分离症状。在一项针对抑郁症患者的研究中,与单独使用氯胺酮相比,氯胺酮和拉莫三嗪没有更强的抗抑郁作用,但在这项研究中只给予了一次氯胺酮输注。一项病例系列描述了在两名双相患者中联合使用的抗抑郁和抗自杀作用。目前关于心境障碍患者的临床研究并未支持拉莫三嗪可降低氯胺酮诱导的分离症状的假设。
分析研究的结果不足以回答任何已提出的问题;然而,它们使我们能够描绘出未来的研究方向。已识别的动物研究表明,氯胺酮和拉莫三嗪联合使用可能具有协同抗抑郁作用。目前的临床研究没有定论。目前尚未发表关于使用多次氯胺酮输注联合拉莫三嗪治疗的大量双相患者的对照研究。有一些证据表明拉莫三嗪可以减轻氯胺酮的副作用,并且有报道表明拉莫三嗪可以减少氯胺酮的渴望。需要进行更多具有随访的研究,以调查双相患者中氯胺酮-拉莫三嗪联合治疗的效果。